Fehmiye Funda Karkın Gürel

Fehmiye Funda Karkın Gürel

Auto-generated profile, based on publicly available information

Fehmiye Funda Karkın Gürel

Department of Pediatrics, Ankara Bilkent City Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
BDBÜŞRA DEMİRCİ
BÜŞRA DEMİRCİ
BGBelgin Gülhan
Belgin Gülhan
SKSevinc Puren Yucel Karakaya
Sevinc Puren Yucel Karakaya
FGFehmiye Funda Karkın Gürel
Fehmiye Funda Karkın Gürel
BHBengü Hakbilen
Bengü Hakbilen
AÖAslınur Özkaya-Parlakay
Aslınur Özkaya-Parlakay
Background Enterococcal bloodstream infections (EBIs) are increasingly concerning in pediatric patients due to high morbidity, mortality, and antimicrobial resistance, especially vancomycin-resistant enterococci (VRE). This study aimed to evaluate clinical characteristics, species distribution, risk factors, and outcomes of pediatric EBSIs, focusing on VRE and mortality predictors. Methods This retrospective study analyzed 368 children with confirmed enterococcal bacteremia. Demographic, clinical, microbiological, and treatment data were collected. Comparative analyses were done between species, VRE vs. vancomycin-susceptible enterococci (VSE), and mortality outcomes. Logistic regression identified independent risk factors for VRE and mortality. Results Mean age was 5.2 ± 3.8 years, with 53.8% male. Common underlying conditions included hematologic/oncologic malignancies (20.9%), necrotizing enterocolitis (18.8%), and neurological disorders (16.8%). E. faecalis (51.9%) and E. faecium (41.6%) were the most frequent isolates, with VRE detected in 10.9%, predominantly among E. faecium isolates. Older age, prior VRE colonization, E. faecium infection, total parenteral nutrition (TPN) use, and persistent bacteremia significantly increased the risk of VRE infection. The overall 30-day mortality rate was 9.0%, while the total mortality during follow-up reached 20.7%. Thirty-day mortality was independently predicted by prior carbapenem use (OR = 3.2), whereas overall mortality was significantly associated with receipt of TPN (OR = 1.9), ICU admission (OR = 6.5), persistent bacteremia (OR = 3.6), and prior vancomycin use (OR = 2.2). Conclusion Pediatric EBSIs are linked with significant comorbidities and mortality. VRE presence, persistent infection, and prior broad-spectrum antibiotic use increase mortality risk, highlighting the need for antimicrobial stewardship and risk-based management.